EW - Comprehensive Filing Intelligence

FY 2025•10-K•Filed Feb 25, 2026
5.0/10
Filing Health:CAUTION

Notable concerns that warrant closer review

Executive Summary

Capital allocation in 2025 was focused on share repurchases, with significant activity noted.. Multiple significant lawsuits are ongoing, with management unable to predict their financial impact, creating notable uncertainty.. Total net sales increased by 11.5% to $6.1 billion in 2025.

Top Concerns

  • !Gross profit margin declined due to higher operational expenses, while net income was impacted by increased personnel costs, impairments, and litigation.
  • !Significant legal and tax uncertainties persist, particularly concerning transfer pricing matters with the IRS, which could materially impact financial results.
  • !Significant intangible asset impairment charge in 2025 ($40.0 million).
  • !Multiple significant lawsuits are ongoing, with management unable to predict their financial impact, creating notable uncertainty.
  • !The company has accrued $146.2 million for legal settlements and proceedings, with potential for material impact from ongoing litigation.

Top Positives

  • +Revenue growth was driven by TAVR and TMTT products, with continued strength in Surgical Structural Heart.
  • +The company maintains a strong liquidity position with substantial cash reserves and an undrawn revolving credit facility.

Analysis Dimensions

Our 5-pass AI analysis examines this filing across multiple dimensions. Each dimension score is derived from direct analysis of SEC filing text.

Narrative Intelligence

7.0/10

Management tone is confidently optimistic with focus on sales growth of our tavr and tmtt products.

Full analysis includes: tone changes vs prior quarter, margin driver breakdown, forward guidance analysis, strategic priorities.

Accounting Quality

7.0/10

Earnings quality shows moderate accounting practices.

Full analysis includes: reserve and allowance changes, non-recurring item analysis, stock-based compensation impact, disclosure concerns.

Hidden Liabilities

Off-balance sheet risk is moderate with $146.2 million in identified exposure.

Full analysis includes: cloud and purchase commitments, VIE/SPE exposure, covenant compliance status, refinancing risk assessment.

Risk Landscape

3.0/10

Overall risk profile shows regulatory compliance and product approvals as primary concern.

Full analysis includes: 8 risk categories with severity, new vs escalated risks, management response assessment, risk trend analysis.

Segment Performance

8.0/10

Segment health analysis.

Full analysis includes: segment-by-segment revenue breakdown, geographic concentration risk, customer concentration analysis, segment margin trends.